title: Effect of vaccination therapy for acne, using a staphylococci antigenic complex in combination with clindamycin.
abstract: A group of 46 patients with acne vulgaris were prescribed clindamycin in combination with a vaccination therapy using a staphylococci antigenic complex (Polystafana; Sevapharma, Czechia). Acne papulopustulosa was diagnosed in 36 patients and acne indurata in 10 patients. The clinical effect of clindamycin and Polystafana was determined on the basis of the regression of the inflammatory manifestation of acne: regression by 0-30% was considered unsuccessful, by 30-80% satisfactory, and above 80% excellent; the immunomodulation effect of the treatment was evaluated in parallel. The clinical effect was excellent in 21 patients with acne papulopustulosa and in 6 with acne indurata; it was accompanied by pronounced immunomodulation effect as both cellular and humoral immunity was also tended to return to normal values. A satisfactory clinical effect was observed in 15 patients with acne papulopustulosa, whose cellular immunity component was also stimulated. Only 4 patients with acne indurata failed to respond successfully. These were the patients who showed a pronounced deficit of the cellular immunity component persisting even after the treatment. The administration of clindamycin in combination with Polystafana vaccination can be recommended as an effective means for the treatment of acne vulgaris.
authors.affiliation: Department of Dermatology, Faculty of Medicine, Safárik University, 040 66 Kosice, Slovakia.
authors.forename: J
authors.initials: J
authors.lastname: Jautová
authors.forename: E
authors.initials: E
authors.lastname: Dorko
authors.forename: E
authors.initials: E
authors.lastname: Pilipcinec
authors.forename: L
authors.initials: L
authors.lastname: Tkáciková
mesh_terms: D000152:Acne Vulgaris / Q000276:immunology / Q000628:therapy*; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D002648:Child; D002981:Clindamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006801:Humans; D007111:Immunity, Cellular; D013209:Staphylococcal Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014611:Vaccination
chemical_list: D000900:Anti-Bacterial Agents; D000942:Antigens, Bacterial; D013209:Staphylococcal Vaccines; D002981:Clindamycin